NEW YORK — Drug discovery and development firm Crown Bioscience has partnered with Cambridge Quantum Computing (CQC) on the identification of novel cancer treatment biomarkers, the companies said on Wednesday.
Under the terms of the deal, the companies will combine UK-based CQC’s quantum machine algorithms and software development capabilities with CrownBio’s preclinical and translational research expertise and datasets to identify multi-gene biomarkers that can be used in cancer drug discovery.
Additional terms were not disclosed.
This is a syndicated post. Read the original post at Source link .